How it works, simply
It targets an appetite-related hormone pathway distinct from the GLP-1 receptor.
What the evidence tells us
A registered Phase 3 trial shows a research plan, not proof that the treatment succeeded.
Watch with PEP 7
A short introduction; the sources and limitations remain important.
Open video guide
Video guides are coming soon.
Risks and open questions
This guide does not establish a safe dose, interaction profile or long-term safety for self-use. Effects reported for one route or formulation may not apply to another.
Research and education only. PepGuide does not recommend medicines, doses or protocols.
Technical details and study context
Mechanism: Selectively activates amylin receptors to affect satiety and energy intake.
Sponsor or developer: Eli Lilly and Company
Studied or labeled topics: Obesity
2026-09-23: ENLIGHTEN-1 is a Phase 3 obesity study; a registered study is not evidence of a successful outcome.
Commercial blend names and research vials do not inherit a medicine’s approval or manufacturing controls.
Sources and review dates
- ClinicalTrials.gov: ENLIGHTEN-1 ↗ · Registry · 2026-09-23
- Lilly: ENLIGHTEN-1 study information ↗ · Sponsor · 2026-09-23
Readability updated October 10, 2026. Evidence review: September 23, 2026 (listed facts only). A wording update is not a new clinical review.